Related references
Note: Only part of the references are listed.Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
Jennifer Y. Ge et al.
CASE REPORTS IN ONCOLOGY (2021)
Margetuximab for the treatment of HER2-positive metastatic breast cancer
Paolo Tarantino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
Daniel V. T. Catenacci et al.
FUTURE ONCOLOGY (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue
Vrinda Gote et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells
Kashyap R. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
A general Fc engineering platform for the next generation of antibody therapeutics
Da Chen et al.
THERANOSTICS (2021)
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2020)
Antibodies to watch in 2020
Helene Kaplon et al.
MABS (2020)
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
Essia Mezni et al.
CANCERS (2020)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial
Daniel V. T. Catenacci et al.
LANCET ONCOLOGY (2020)
Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Nora Pashayan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics
Anatoly Kiyatkin et al.
SCIENCE SIGNALING (2020)
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Hilma J. van der Horst et al.
CANCERS (2020)
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Ricardo L. B. Costa et al.
NPJ BREAST CANCER (2020)
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
Gaia Griguolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity
Jin Young Moon et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Gwo-Fuang Ho et al.
BMC CANCER (2019)
Neratinib in HER2-Positive Breast Cancer Patients
Rutugandha Paranjpe et al.
ANNALS OF PHARMACOTHERAPY (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Alexey A. Larionov
FRONTIERS IN ONCOLOGY (2018)
Recent Advances in the Treatment of Breast Cancer
Christy W. S. Tong et al.
FRONTIERS IN ONCOLOGY (2018)
A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism
Niken M. Mahaweni et al.
SCIENTIFIC REPORTS (2018)
p95HER2-T cell bispecific antibody for breast cancer treatment
Irene Rius Ruiz et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
J. A. Mestres et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Maria Carmen Ochoa et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion
Christiane Daniela Fichter et al.
JOURNAL OF PATHOLOGY (2017)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin et al.
LANCET ONCOLOGY (2017)
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Christian Kellner et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2017)
Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields
Kristina M. Ilieva et al.
FRONTIERS IN IMMUNOLOGY (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges
Paulo Michel Pinheiro Ferreira et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Tumor Heterogeneity in Breast Cancer
Gulisa Turashvili et al.
FRONTIERS IN MEDICINE (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Helen Gharwan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
Amelie Schramm et al.
BREAST CARE (2015)
Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes
ChunLing Dai et al.
ONCOTARGET (2015)
A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies
Xuejun Fan et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Identification of an ADAM17 Cleavage Region in Human CD16 (FcγRIII) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells
Yawu Jing et al.
PLOS ONE (2015)
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
Narendiran Rajasekaran et al.
IMMUNOTARGETS AND THERAPY (2015)
Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
Ian Krop et al.
CLINICAL CANCER RESEARCH (2014)
Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
Sohita Dhillon
DRUGS (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
Ichiro N. Maruyama
CELLS (2014)
A single-arm, open-label, phase 2 study of MGAH22 (ma rgetuximab) [fc-optimized chimeric anti-HER2 monoclonal antibody (mAb)] in patients with relapsed or refractory advanced breast cancer whose tumors express HERZ at the 2+level by immunohistochemistry and lack evidence of HERZ gene amplification by FISH
Mark D. Pegram et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
Diana P. English et al.
MOLECULAR DIAGNOSIS & THERAPY (2013)
Targeted therapy in HER2-positive breast cancer (Review)
Shu Guang Li et al.
BIOMEDICAL REPORTS (2013)
Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond
Dimitrios Zardavas et al.
BREAST CANCER MANAGEMENT (2012)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy
JS Ross et al.
ONCOLOGIST (2003)
Share Paper
